Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2026 | One big question with Celia Oreja-Guevara: what MS advance could transform care in the next 3 years?

Celia Oreja-Guevara • 29 Jun 2026
EAN 2026
Multiple Sclerosis and Related Disorders BTK inhibitors Masitinib

Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, discusses the key advances in multiple sclerosis (MS) that could transform care in the next three years. Dr Oreja-Guevara mentions treatments to slow or prevent disease progression, including BTK inhibitors and anti-CD40 antibodies. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Celia Oreja-Guevara

EU approval of tolebrutinib marks new era in progressive multiple sclerosis
1:27
EU approval of tolebrutinib marks new era in progressive multiple sclerosis
Celia Oreja-Guevara • 29 Jun 2026
Detecting and disrupting disability accumulation in MS: a session at EAN 2026
1:57
Detecting and disrupting disability accumulation in MS: a session at EAN 2026
Celia Oreja-Guevara • 29 Jun 2026
Emerging therapeutic strategies for MS at AAN 2026
1:06
Emerging therapeutic strategies for MS at AAN 2026
Celia Oreja-Guevara • 21 Apr 2026
Phase III HERCULES & GEMINI trials: tolebrutinib reduces disability progression in MS
2:30
Phase III HERCULES & GEMINI trials: tolebrutinib reduces disability progression in MS
Celia Oreja-Guevara • 21 Apr 2026

Related Videos

EU approval of tolebrutinib marks new era in progressive multiple sclerosis
1:27
EU approval of tolebrutinib marks new era in progressive multiple sclerosis
Celia Oreja-Guevara • 29 Jun 2026
Efficacy and safety of ofatumumab in real-world practice for MS: multi-centre study
2:01
Efficacy and safety of ofatumumab in real-world practice for MS: multi-centre study
Ana Paz Tamayo • 29 Jun 2026
Detecting and disrupting disability accumulation in MS: a session at EAN 2026
1:57
Detecting and disrupting disability accumulation in MS: a session at EAN 2026
Celia Oreja-Guevara • 29 Jun 2026
A discussion at EAN 2026 on the impact of climate change on neurological diseases
13:26
A discussion at EAN 2026 on the impact of climate change on neurological diseases
Amalia Ghergu et al. • 28 Jun 2026
The content of VJNeurology is intended for healthcare professionals